Abstract
Summary
The global Gene Therapy in Cardiovascular Disorder market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gene Therapy in Cardiovascular Disorder players cover Renovacor, Gene Biotherapeutics, AskBio, Human Stem Cells Institute and Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
LPI (LP Information)' newest research report, the “Gene Therapy in Cardiovascular Disorder Industry Forecast” looks at past sales and reviews total world Gene Therapy in Cardiovascular Disorder sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy in Cardiovascular Disorder sales for 2023 through 2029. With Gene Therapy in Cardiovascular Disorder sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy in Cardiovascular Disorder industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy in Cardiovascular Disorder landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy in Cardiovascular Disorder portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy in Cardiovascular Disorder market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy in Cardiovascular Disorder and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy in Cardiovascular Disorder.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy in Cardiovascular Disorder market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Viral Gene Therapy
Non-viral Gene Therapy
Segmentation by application
Heart Disease
Vascular Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
United States market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gene Therapy in Cardiovascular Disorder is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gene Therapy in Cardiovascular Disorder players cover Renovacor, Gene Biotherapeutics, AskBio, Human Stem Cells Institute and Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
LPI (LP Information)' newest research report, the “Gene Therapy in Cardiovascular Disorder Industry Forecast” looks at past sales and reviews total world Gene Therapy in Cardiovascular Disorder sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy in Cardiovascular Disorder sales for 2023 through 2029. With Gene Therapy in Cardiovascular Disorder sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy in Cardiovascular Disorder industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy in Cardiovascular Disorder landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy in Cardiovascular Disorder portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy in Cardiovascular Disorder market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy in Cardiovascular Disorder and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy in Cardiovascular Disorder.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy in Cardiovascular Disorder market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Viral Gene Therapy
Non-viral Gene Therapy
Segmentation by application
Heart Disease
Vascular Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Gene Therapy in Cardiovascular Disorder Market Size 2018-2029
2.1.2 Gene Therapy in Cardiovascular Disorder Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Gene Therapy in Cardiovascular Disorder Segment by Type
2.2.1 Viral Gene Therapy
2.2.2 Non-viral Gene Therapy
2.3 Gene Therapy in Cardiovascular Disorder Market Size by Type
2.3.1 Gene Therapy in Cardiovascular Disorder Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Gene Therapy in Cardiovascular Disorder Market Size Market Share by Type (2018-2023)
2.4 Gene Therapy in Cardiovascular Disorder Segment by Application
2.4.1 Heart Disease
2.4.2 Vascular Disease
2.5 Gene Therapy in Cardiovascular Disorder Market Size by Application
2.5.1 Gene Therapy in Cardiovascular Disorder Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Gene Therapy in Cardiovascular Disorder Market Size Market Share by Application (2018-2023)
3 Gene Therapy in Cardiovascular Disorder Market Size by Player
3.1 Gene Therapy in Cardiovascular Disorder Market Size Market Share by Players
3.1.1 Global Gene Therapy in Cardiovascular Disorder Revenue by Players (2018-2023)
3.1.2 Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy in Cardiovascular Disorder Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Gene Therapy in Cardiovascular Disorder by Regions
4.1 Gene Therapy in Cardiovascular Disorder Market Size by Regions (2018-2023)
4.2 Americas Gene Therapy in Cardiovascular Disorder Market Size Growth (2018-2023)
4.3 APAC Gene Therapy in Cardiovascular Disorder Market Size Growth (2018-2023)
4.4 Europe Gene Therapy in Cardiovascular Disorder Market Size Growth (2018-2023)
4.5 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size Growth (2018-2023)
5 Americas
5.1 Americas Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023)
5.2 Americas Gene Therapy in Cardiovascular Disorder Market Size by Type (2018-2023)
5.3 Americas Gene Therapy in Cardiovascular Disorder Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2023)
6.2 APAC Gene Therapy in Cardiovascular Disorder Market Size by Type (2018-2023)
6.3 APAC Gene Therapy in Cardiovascular Disorder Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gene Therapy in Cardiovascular Disorder by Country (2018-2023)
7.2 Europe Gene Therapy in Cardiovascular Disorder Market Size by Type (2018-2023)
7.3 Europe Gene Therapy in Cardiovascular Disorder Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gene Therapy in Cardiovascular Disorder by Region (2018-2023)
8.2 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Type (2018-2023)
8.3 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Gene Therapy in Cardiovascular Disorder Market Forecast
10.1 Global Gene Therapy in Cardiovascular Disorder Forecast by Regions (2024-2029)
10.1.1 Global Gene Therapy in Cardiovascular Disorder Forecast by Regions (2024-2029)
10.1.2 Americas Gene Therapy in Cardiovascular Disorder Forecast
10.1.3 APAC Gene Therapy in Cardiovascular Disorder Forecast
10.1.4 Europe Gene Therapy in Cardiovascular Disorder Forecast
10.1.5 Middle East & Africa Gene Therapy in Cardiovascular Disorder Forecast
10.2 Americas Gene Therapy in Cardiovascular Disorder Forecast by Country (2024-2029)
10.2.1 United States Gene Therapy in Cardiovascular Disorder Market Forecast
10.2.2 Canada Gene Therapy in Cardiovascular Disorder Market Forecast
10.2.3 Mexico Gene Therapy in Cardiovascular Disorder Market Forecast
10.2.4 Brazil Gene Therapy in Cardiovascular Disorder Market Forecast
10.3 APAC Gene Therapy in Cardiovascular Disorder Forecast by Region (2024-2029)
10.3.1 China Gene Therapy in Cardiovascular Disorder Market Forecast
10.3.2 Japan Gene Therapy in Cardiovascular Disorder Market Forecast
10.3.3 Korea Gene Therapy in Cardiovascular Disorder Market Forecast
10.3.4 Southeast Asia Gene Therapy in Cardiovascular Disorder Market Forecast
10.3.5 India Gene Therapy in Cardiovascular Disorder Market Forecast
10.3.6 Australia Gene Therapy in Cardiovascular Disorder Market Forecast
10.4 Europe Gene Therapy in Cardiovascular Disorder Forecast by Country (2024-2029)
10.4.1 Germany Gene Therapy in Cardiovascular Disorder Market Forecast
10.4.2 France Gene Therapy in Cardiovascular Disorder Market Forecast
10.4.3 UK Gene Therapy in Cardiovascular Disorder Market Forecast
10.4.4 Italy Gene Therapy in Cardiovascular Disorder Market Forecast
10.4.5 Russia Gene Therapy in Cardiovascular Disorder Market Forecast
10.5 Middle East & Africa Gene Therapy in Cardiovascular Disorder Forecast by Region (2024-2029)
10.5.1 Egypt Gene Therapy in Cardiovascular Disorder Market Forecast
10.5.2 South Africa Gene Therapy in Cardiovascular Disorder Market Forecast
10.5.3 Israel Gene Therapy in Cardiovascular Disorder Market Forecast
10.5.4 Turkey Gene Therapy in Cardiovascular Disorder Market Forecast
10.5.5 GCC Countries Gene Therapy in Cardiovascular Disorder Market Forecast
10.6 Global Gene Therapy in Cardiovascular Disorder Forecast by Type (2024-2029)
10.7 Global Gene Therapy in Cardiovascular Disorder Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Renovacor
11.1.1 Renovacor Company Information
11.1.2 Renovacor Gene Therapy in Cardiovascular Disorder Product Offered
11.1.3 Renovacor Gene Therapy in Cardiovascular Disorder Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Renovacor Main Business Overview
11.1.5 Renovacor Latest Developments
11.2 Gene Biotherapeutics
11.2.1 Gene Biotherapeutics Company Information
11.2.2 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Product Offered
11.2.3 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Gene Biotherapeutics Main Business Overview
11.2.5 Gene Biotherapeutics Latest Developments
11.3 AskBio
11.3.1 AskBio Company Information
11.3.2 AskBio Gene Therapy in Cardiovascular Disorder Product Offered
11.3.3 AskBio Gene Therapy in Cardiovascular Disorder Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 AskBio Main Business Overview
11.3.5 AskBio Latest Developments
11.4 Human Stem Cells Institute
11.4.1 Human Stem Cells Institute Company Information
11.4.2 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Product Offered
11.4.3 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Human Stem Cells Institute Main Business Overview
11.4.5 Human Stem Cells Institute Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Gene Therapy in Cardiovascular Disorder Product Offered
11.5.3 Novartis Gene Therapy in Cardiovascular Disorder Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
12 Research Findings and Conclusion